Related Experiment Video
Updated: Apr 25, 2026
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts
Stephan Kruger1, Michael Haas1, Steffen Ormanns1
1Stephan Kruger, Michael Haas, Sibylle Bächmann, Volker Heinemann, Stefan Boeck, Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, D-81377 Munich, Germany.
Abstract:
Pancreatic ductal adenocarcinoma (PDA) is one of the major causes for cancer death worldwide. Treatment of metastatic disease remains challenging as only certain patients benefit from advances made with the intensified chemotherapy regimen folinic acid, irinotecan and oxaliplatin, the epidermal growth factor receptor inhibitor erlotinib or the recently FDA-approved nab-paclitaxel. Up to date, no established approach for prediction of treatment response or specific treatment allocation exists. Translational research was able to identify a number of potential biomarkers that might help to improve the dismal prognosis of PDA by facilitating upfront treatment allocation. This topic highlight is focused on current evidence on potential biomarkers for tumor biology, prognosis and prediction of treatment efficacy.
Insights
Pancreatic ductal adenocarcinoma (PDA) treatment response is hard to predict. Identifying biomarkers may help allocate the right therapy for better patient outcomes.
Area of Science:
- Oncology
- Translational Research
- Biomarker Discovery
Background:
- Pancreatic ductal adenocarcinoma (PDA) is a leading cause of cancer mortality globally.
- Current treatments for metastatic PDA offer limited benefit to specific patient groups.
- No reliable methods exist for predicting treatment response or guiding therapy selection in PDA.
Purpose of the Study:
- To review current evidence on potential biomarkers for PDA.
- To explore biomarkers related to tumor biology, prognosis, and treatment efficacy.
- To highlight advancements that may improve PDA patient outcomes through targeted therapies.
Main Methods:
- Review of translational research findings.
- Analysis of potential biomarkers for PDA.
- Focus on evidence for tumor biology, prognosis, and treatment prediction.
Main Results:
- Several potential biomarkers have been identified through translational research.
- These biomarkers show promise for improving the prognosis of PDA.
- Biomarkers may facilitate upfront treatment allocation for PDA patients.
Conclusions:
- Biomarker discovery is crucial for improving PDA treatment strategies.
- Predictive biomarkers can enable personalized medicine approaches in PDA.
- Further research is needed to validate and implement these biomarkers in clinical practice.
